MRKON Risks Explained: KEYTRUDA Dependence, Patent Expiry, Clinical Trials and Tokenized Stock Risk
The MRKON tokenized asset provides economic exposure to Merck & Co. equity, introducing a unique layer of risk that combines traditional pharmaceutical market volatility with blockchain-specific trading dynamics. Merck faces significant concentration risk due to its reliance on the KEYTRUDA franchise, which faces a U.S. patent expiry in 2028. While the company is transitioning toward KEYTRUDA QLEX and other growth drivers, investors must distinguish between scientific pipeline potential and actual commercial revenue realization. Tokenized equity holders face additional risks, including potential liquidity disparities compared to traditional MRK shares and the possibility that tokenized markets react to news outside of standard U.S. trading hours. Furthermore, tokenized assets do not necessarily grant the same legal shareholder rights as conventional equity ownership. Analysts emphasize that the underlying pharmaceutical business fundamentals, such as clinical trial success and regulatory approvals, remain the primary drivers of value. Consequently, the tokenization layer does not alter the inherent probability tree of Merck's drug development pipeline, requiring investors to monitor both legacy product performance and future growth metrics.